Physician profile
Stephen Mcnally
NPI 1417622424
$3,580.06
in general payments reported to CMS, 2019-2025
33 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.58 · 2022: $93.63 · 2023: $1,135 · 2024: $845 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,037 · Travel and Lodging: $235 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.84 |
| Travel and Lodging | $235.13 |
| Education | $197.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $552.77 | 2025 | Axonics |
| Glaxosmithkline, LLC. | $389.76 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Teleflex LLC | $364.22 | 2022-2025 | Urolift, Barrigel, Solesta |
| Pfizer INC. | $243.89 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $173.00 | 2023-2024 | Xarelto |
| Abbvie INC. | $168.55 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $146.88 | 2023-2024 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $144.39 | 2025 | Xtandi, Padcev |
| Dexcom, INC. | $122.88 | 2023-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $114.40 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $112.94 | 2025 | Orgovyx, Gemtesa |
| Amgen INC. | $111.86 | 2023-2024 | Repatha, Otezla, Evenity |
| Seagen INC. | $84.99 | 2025 | |
| Endo USA, INC. | $80.00 | 2025 | Xiaflex |
| Astrazeneca Pharmaceuticals LP | $78.70 | 2023-2024 | Airsupra, Farxiga |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $72.44 | 2023 | Korlym |
| Procept Biorobotics Corporation | $72.08 | 2025 | |
| Novo Nordisk INC | $68.00 | 2023-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $67.34 | 2023-2024 | Mounjaro |
| Kerecis Limited | $60.63 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Tela Bio, INC. | $50.88 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Novartis Pharmaceuticals Corporation | $45.56 | 2023-2024 | |
| Mylan Specialty L.P. | $39.63 | 2023 | Yupelri |
| Smith+Nephew, INC. | $32.14 | 2022 | |
| Intuitive Surgical, INC. | $27.39 | 2022 | |
| Agiliti Surgical, INC. | $24.23 | 2025 | Koelis Trinity Mri/US Fusion |
| Eisai INC. | $22.83 | 2024 | |
| Bioventus LLC | $22.25 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.42 | 2024 | Jardiance |
| Exact Sciences Corporation | $18.63 | 2024 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $16.85 | 2024 | Nuzyra |
| Heron Therapeutics, INC. | $16.58 | 2021 | |
| Calyxo, INC. | $13.95 | 2025 | Cvac Aspiration System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mcnally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.